PT-141 (Bremelanotide) Pharmacokinetics: How This HSDD Drug Moves Through Your Body

What Is Bremelanotide and Why Does Its Pharmacokinetics Matter?

Bremelanotide is not a hormone and not a phosphodiesterase inhibitor. It is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts on the central nervous system to modulate sexual desire rather than genital blood flow. Understanding how the drug moves through your body matters because its absorption speed determines when you inject it, its CNS penetration explains why it works, and its metabolic pathway determines which other medications interact with it.

The FDA approved bremelanotide (brand name Vyleesi) in June 2019 specifically for premenopausal women with acquired, generalized HSDD, making it one of only two FDA-approved pharmacologic treatments for female sexual interest/arousal disorder [as classified in DSM-5]. The other approved option is flibanserin (Addyi), a daily oral agent with a completely different mechanism.

Because HSDD affects an estimated one in ten premenopausal women in the United States, the pharmacokinetic profile of any on-demand treatment is clinically significant. How fast it works, how long it lasts, and how reliably it behaves across the menstrual cycle all shape whether a woman will actually use it.

Mechanism of Action: Central Melanocortin Signaling

Bremelanotide works in the brain, not in the genitals. That distinction separates it mechanistically from every other sexual-dysfunction drug on the market.

The Melanocortin Receptor System

The melanocortin system comprises five G-protein-coupled receptor subtypes (MC1R through MC5R). Bremelanotide binds with high affinity to MC4R, MC3R, and MC1R. MC4R in the hypothalamus and limbic system is the receptor subtype most associated with sexual motivation and appetite regulation. MC3R activation is linked to energy homeostasis. MC1R, located on melanocytes, explains the transient skin hyperpigmentation some women notice after repeated dosing.

When bremelanotide binds MC4R in the paraventricular nucleus of the hypothalamus and in mesolimbic dopaminergic circuits, it increases dopamine release and modulates oxytocin signaling. The net effect is an increase in sexual motivation at the neurological level, not a peripheral vasodilatory effect.

How This Differs From Phosphodiesterase-5 Inhibitors

Sildenafil (Viagra) and related drugs increase genital blood flow by blocking PDE-5 in smooth muscle. They do not affect desire. Bremelanotide does the opposite: it changes desire centrally but has no direct vascular action in the pelvis. This is why bremelanotide was studied in women (where desire deficits are the predominant HSDD complaint) while PDE-5 inhibitors have limited evidence in women with HSDD specifically.

Menstrual Cycle and Hormonal Context

The melanocortin system is estrogen-sensitive. Estrogen upregulates hypothalamic MC4R expression, which means MC4R density and signaling capacity are not static across your cycle. Receptor expression is relatively higher in the follicular and periovulatory phases when estrogen peaks. No published trial has prospectively measured bremelanotide efficacy stratified by cycle phase, which is a genuine evidence gap. The RECONNECT trial tracked desire and distress over 24 weeks but did not report phase-stratified outcomes.

Absorption: The Subcutaneous Route in Women

Bremelanotide is given only subcutaneously. An oral formulation is not available because peptides are degraded in the GI tract before meaningful systemic absorption can occur.

Bioavailability and Injection Technique

Subcutaneous bioavailability of bremelanotide is approximately 100% relative to intravenous dosing, though the FDA label describes absolute bioavailability as not formally established by the classic oral-vs-IV comparison since there is no oral formulation. Phase 1 data show that the subcutaneous route reliably delivers the peptide into the systemic circulation without first-pass hepatic degradation.

You inject the 1.75 mg dose into the abdomen or thigh using a single-use autoinjector. Injection site affects absorption rate modestly: abdominal injection produces a slightly faster rise to peak concentration than thigh injection, similar to what is seen with insulin analogs. The FDA prescribing information for Vyleesi does not mandate a specific site but recommends rotating to avoid local reactions.

Time to Peak Concentration

Mean time to maximum plasma concentration (Tmax) is approximately 45 to 60 minutes after subcutaneous injection, which is why the label instructs women to inject 45 minutes before anticipated sexual activity. Peak plasma concentrations (Cmax) following a 1.75 mg dose average roughly 3 to 4 ng/mL in pharmacokinetic studies from the clinical development program.

Body weight influences Cmax. Women with higher body weight tend to show lower Cmax for the same fixed 1.75 mg dose, following standard peptide PK principles. No dose adjustment is currently recommended by the FDA based on weight, but this represents a clinically relevant observation for women with obesity who report attenuated response.

Distribution: Where Bremelanotide Goes

Volume of Distribution and Protein Binding

Bremelanotide has a volume of distribution of approximately 40 L after intravenous administration, suggesting moderate distribution beyond the vascular compartment but without extensive tissue sequestration. Plasma protein binding is approximately 21%, which is low. Low protein binding means that drug interactions driven by protein displacement are not a significant concern, and it also means free drug concentrations track total plasma concentrations closely.

Blood-Brain Barrier Penetration

This is where bremelanotide is pharmacologically unusual. As a cyclic heptapeptide, bremelanotide is too large to cross the blood-brain barrier by passive diffusion in the way small-molecule drugs do. Animal data from the early development program showed that intranasal administration (the original delivery route, later abandoned due to transient blood pressure effects) achieved CNS levels sufficient to activate hypothalamic MC4R. With subcutaneous dosing, CNS penetration is thought to occur through fenestrated capillaries in circumventricular organs, particularly the area postrema and the median eminence, which lack a complete blood-brain barrier.

The clinical implication is real: CNS activity occurs at plasma concentrations well below what would be predicted for a molecule of this size by standard CNS penetration models. This is not an anomaly but a property of melanocortin peptides generally.

Metabolism: How Your Body Breaks Down Bremelanotide

Bremelanotide does not go through the cytochrome P450 enzyme system. This is clinically important for women on hormonal contraceptives, antidepressants, or other CYP-metabolized medications.

Hydrolysis, Not CYP Oxidation

The primary metabolic pathway is hydrolysis of peptide bonds by ubiquitous proteolytic enzymes throughout the body. No single organ is the rate-limiting site of metabolism. The major metabolite is a ring-opened linear heptapeptide, designated metabolite M1, which is pharmacologically inactive at melanocortin receptors. Additional minor metabolites arise from further sequential peptide bond hydrolysis.

Because hepatic CYP450 isoforms are not involved, conditions that induce or inhibit CYP3A4, CYP2D6, or other major CYP enzymes do not alter bremelanotide exposure. This matters specifically for women taking enzyme-inducing anticonvulsants (carbamazepine, phenytoin) or the antibiotic rifampin, which would otherwise reduce efficacy of CYP-metabolized drugs.

Effect on Naltrexone and Indomethacin Absorption

One pharmacokinetic drug interaction that is clearly documented: bremelanotide decreases the rate of absorption of naltrexone and indomethacin through delayed gastric emptying. Peak plasma concentrations of these co-administered oral drugs are reduced and delayed. This matters clinically because some women take naltrexone (as part of naltrexone/bupropion for weight management, or for alcohol use disorder) and may need to consider the timing of their doses.

Elimination: Half-Life and Renal Excretion

Terminal Half-Life

The terminal elimination half-life of bremelanotide is approximately 2.7 hours. Given the Tmax of roughly one hour, most women will have cleared the majority of active drug within 6 to 8 hours after injection. This half-life also explains why the label limits use to one injection in 24 hours and no more than one injection per anticipated sexual activity.

Renal Excretion

Approximately 64% of a bremelanotide dose is recovered in urine, primarily as metabolites rather than intact peptide. About 22% is excreted in feces. The kidney is therefore the dominant elimination organ for the hydrolysis products, not for the parent compound.

Renal impairment and dosing: a practical framework for women.

Women experience chronic kidney disease (CKD) at substantial rates, and renal function declines with age through perimenopause and beyond. The FDA does not recommend dose adjustment for mild-to-moderate renal impairment, but Vyleesi has not been studied in women with severe renal impairment (eGFR <30 mL/min) or end-stage renal disease. Exposure may accumulate in severe CKD given the renal route of metabolite clearance. Until studies are done, use in severe CKD should be approached with caution and individual clinical judgment rather than assumed safety.

Hepatic Impairment

Because the liver is not the sole or primary metabolic site, mild-to-moderate hepatic impairment does not meaningfully change bremelanotide exposure. No dose adjustment is required in Child-Pugh A or B hepatic impairment. Severe hepatic impairment (Child-Pugh C) has not been studied.

Sex-Specific Pharmacokinetics: What Being a Woman Changes

The entire clinical development program for bremelanotide was conducted in women, which is unusual in drug development and means the PK data are genuinely female-specific rather than extrapolated from male populations. This is a genuine evidence advantage compared with most cardiovascular and metabolic drugs.

Hormonal Contraceptive Interactions

Bremelanotide's delayed gastric emptying effect on oral drug absorption raises a specific concern for women taking combined oral contraceptives. If a woman takes her daily oral contraceptive pill within the window of bremelanotide's gastric motility effect (roughly 1 to 4 hours post-injection), absorption of the contraceptive may be reduced. The FDA label recommends taking oral medications at least one hour before bremelanotide injection or waiting at least two hours after injection. Women who use non-oral contraception (patch, ring, IUD, implant, injection) are not affected by this interaction.

Body Composition and PK Variability

Women have a higher percentage of body fat than men at equivalent BMI, and this influences the subcutaneous absorption depot. Adipose tissue blood flow, which determines how quickly a subcutaneous peptide is absorbed into systemic circulation, is lower in subcutaneous abdominal fat in women with obesity compared with lean women. This may contribute to increased interindividual PK variability in women with higher body fat percentages, though no published PK substudy has formally characterized this relationship for bremelanotide.

Perimenopausal and Postmenopausal Women

The FDA indication is explicitly limited to premenopausal women. The RECONNECT trial enrolled premenopausal women aged 18-55 with a confirmed DSM-5 diagnosis of HSDD. Women in perimenopause with irregular cycles but who still meet the premenopausal definition may qualify, but the data are sparse in this subgroup. Postmenopausal women were excluded from the key trial; any use in this group is off-label and lacks PK or efficacy data.

The estrogen-dependence of hypothalamic MC4R expression is a relevant biological reason to expect attenuated pharmacodynamic response in postmenopausal women even if PK parameters were similar, since lower estrogen reduces the receptor density that bremelanotide is targeting. This remains an unstudied hypothesis.

Clinical Efficacy: What the RECONNECT Trial Found

The RECONNECT program consisted of two phase 3, randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD. The pooled results, published in Obstetrics & Gynecology in 2019, showed that bremelanotide-treated women reported a statistically significant increase in satisfying sexual events (SSEs) and a significant decrease in distress related to low sexual desire compared with placebo over 24 weeks of as-needed use.

Specifically, the mean change from baseline in the Female Sexual Function Index desire domain score was approximately 0.5 points greater with bremelanotide versus placebo, which was statistically significant but modest in absolute magnitude. The RECONNECT authors stated directly: "Bremelanotide significantly improved sexual desire and decreased distress associated with low sexual desire in women with HSDD." The most common adverse effects were nausea (40%), flushing (20%), and injection site reactions, all consistent with the PK profile: nausea peaks near Tmax (1 hour), aligns with the rapid CNS and gastric exposure, and typically resolves within 2 hours.

Pregnancy, Lactation, and Contraception Requirements

Bremelanotide is contraindicated in pregnancy. This is not a precautionary label statement; it reflects teratogenic signals in animal studies. Stop bremelanotide before attempting to conceive.

Animal Teratogenicity Data

In animal reproduction studies, bremelanotide administered to pregnant rats and rabbits caused fetal harm at doses producing exposures several-fold above the recommended human dose. Observed effects included reduced fetal weight and increased post-implantation loss. There are no adequate human data on bremelanotide use during pregnancy because its use in pregnancy has not been studied and would not be ethically approved given the animal findings.

If Pregnancy Occurs During Use

Palatin Technologies maintains a pregnancy exposure registry (1-800-590-3033). If a woman becomes pregnant while using bremelanotide, she should stop immediately and report the exposure to the registry. Given the short half-life of 2.7 hours, the drug will be cleared within approximately 24 hours of the last dose.

Lactation

It is not known whether bremelanotide is excreted in human breast milk. No lactation studies have been conducted. Given the drug's peptide nature, significant oral bioavailability in a nursing infant would be unlikely (peptides are degraded in the infant gut), but this remains unproven. As a precaution, the manufacturer recommends that women not breastfeed while using bremelanotide. Women who are actively breastfeeding and have HSDD should discuss other management strategies with their clinician.

Contraception Requirement

Because bremelanotide is used as-needed and not as a continuous daily therapy, the contraception requirement depends on whether pregnancy is desired. Women who are sexually active and not seeking pregnancy should use reliable contraception while using bremelanotide, and should be aware of the oral contraceptive absorption interaction described above. Non-oral methods (hormonal IUD, copper IUD, implant, injectable progestin) avoid this interaction entirely and are pharmacokinetically the simplest choice when combining with bremelanotide.

Who This Is Right For and Who Should Avoid It

Women Who May Benefit

• Premenopausal women with an established DSM-5 diagnosis of acquired, generalized HSDD (desire loss not explained by relationship or medical factors alone)
• Women who prefer an as-needed approach over daily pharmacotherapy (unlike flibanserin, which requires daily dosing)
• Women on CYP-metabolized medications where a non-CYP drug offers a cleaner interaction profile
• Women who have tried and not tolerated flibanserin, or for whom flibanserin is contraindicated (e.g., alcohol use, hepatic impairment)

Women Who Should Avoid It

• Pregnant women or those actively trying to conceive. This is an absolute contraindication.
• Women with cardiovascular disease or uncontrolled hypertension. Bremelanotide can cause transient increases in blood pressure (mean 2-4 mmHg systolic) peaking at approximately 4 hours post-dose. The FDA label contraindicates bremelanotide in women with cardiovascular disease.
• Postmenopausal women. Currently off-label with no efficacy or safety data specific to this group.
• Women with severe renal impairment or end-stage renal disease. Insufficient data exist.
• Women taking medications where timing adjustments for oral absorption are not feasible (certain narrow-therapeutic-index drugs).

PCOS and Hormonal Acne

Women with PCOS may have concurrent HSDD driven by hormonal dysregulation, androgen excess, and metabolic distress. Bremelanotide acts centrally and does not alter androgen levels or insulin signaling, so it does not treat the underlying PCOS. MC1R activation does cause transient focal hyperpigmentation in some women, which may be more noticeable in women with darker skin tones or existing acanthosis nigricans from PCOS-related insulin resistance. This is a cosmetic concern, not a systemic one, but worth discussing before starting therapy.

Transient Hyperpigmentation: A PK-Linked Adverse Effect

Focal hyperpigmentation of the face, gums, and breast occurs in approximately 1% of women using bremelanotide, and is directly attributable to MC1R agonism on melanocytes. This is dose- and exposure-dependent. With the 1.75 mg subcutaneous dose and the 2.7-hour half-life, cumulative MC1R stimulation remains low with as-needed use. However, women who use bremelanotide more frequently than recommended may face higher cumulative MC1R exposure and greater hyperpigmentation risk. The label states that hyperpigmentation may be permanent if it develops; the FDA recommends no more than one dose per 24 hours and no more than approximately eight doses per month to limit this risk.

Evidence Gaps: Where Women's Data Is Thin

Women have historically been underrepresented in drug trials, but bremelanotide is one case where the trial population was entirely female by design. Still, meaningful gaps remain:

• Cycle-phase PK/PD stratification. No published trial has measured whether bremelanotide efficacy or plasma levels differ meaningfully across menstrual cycle phases, despite the clear estrogen-sensitivity of MC4R.
• Perimenopause and postmenopause. RECONNECT excluded postmenopausal women. Given that HSDD is highly prevalent in perimenopause and menopause, this represents the largest unmet evidence gap.
• Long-term safety beyond 52 weeks. The open-label extension of RECONNECT ran for 52 weeks. Data beyond one year of cumulative exposure are not available.
• Racial and ethnic PK variability. Melanocortin signaling has known variation by ethnicity (relevant to skin hyperpigmentation via MC1R), but formal PK subgroup analyses by race and ethnicity have not been published in the peer-reviewed literature.
• Interaction with SSRIs and SNRIs. Many women with HSDD are also on antidepressants that themselves cause sexual dysfunction. Formal PK interaction studies between bremelanotide and SSRIs or SNRIs are not available, though CYP-based interactions are not predicted given bremelanotide's non-CYP metabolism.

If your prescribing clinician is considering bremelanotide for you and any of these scenarios apply, ask specifically what evidence exists for your situation. Honest acknowledgment of these gaps is part of appropriate informed consent.